The researchers conclude from these findings that there remains insufficient evidence to provide guidance on the use of cannabinoids for treating mental disorders within a regulatory framework.
A commentary notes that in light of the paucity of evidence, the absence of good quality evidence for efficacy, and the known risk of cannabinoids, their use as treatments for psychiatric disorders cannot be justified at present. It adds that if cannabinoids are to be used in the treatment of psychiatric disorders, they should first be tested in randomised controlled trials and subjected to the same regulatory approval process as other prescription medicines.